Public procurement notice: Voluntary Ex Ante Transparency Notice
Published: 2022-06-20
Buyer: SYKEHUSINNKJØP HF
Country: NO
Contract type: Supplies
Procedure: Contract award without prior publication
CPV classification: 33600000: Pharmaceutical products
Estimated value: 510000 NOK
Award criteria: Lowest price

Technical requirements: Voluntary ex-ante transparency notice - supplementary contract LIS 2201b Zolpidem tablets, ENDOS electronically identifiable, ATC code N05CF02
Sykehusinnkjøp HF, Divisjon legemidler (LIS) is collecting tenders for medicines that are used by the Health Trusts. LIS has previously announced and implemented an open tender contest for non-parenteral special pharmaceutical preparations (LIS 2201b). The contest includes active ingredients in accordance with the tender documentation, annex 3 - the Active Ingredients List.
A contract was not signed for the sub-delivery in question, (sub-delivery 776, ATC code N05CF02, Zolpidem, Tablet/capsel, Single dose, electronically identifiable). Therefore there is still a need to enter into a new contract.
Sykehusinnkjøp HF, Divisjon legemidler (LIS) is collecting tenders for medicines that are used by the Health Trusts. LIS has previously announced and implemented an open tender contest for non-parenteral special pharmaceutical preparations (LIS 2001b). The contest includes active ingredients in accordance with the tender documentation, annex 3 - the Active Ingredients List.
A contract was not signed for the sub-delivery in question, (sub-delivery 776, ATC code N05CF02, Zolpidem, Tablet/capsel, Single dose, electronically identifiable). Therefore there is still a need to enter into a new contract.
Due to this, LIS intends to enter into contracts between the regional health trusts (the Contracting Authorities) and Sanofi-Aventis Norge AS (the Supplier) as an additional contract to LIS 2201b, i.e., the scope and length of the contract must follow the mentioned procurement (including access to extensions and terminations), without a new contest being held for this ingredient. The health companies that are under the regional health trusts have an option to enter into the contracts. The same applies for non-profit institutions/hospitals with an operational contract with each health region.
LIS has explored the market situation and is of the opinion that it is impossible to hold a new contest or that a supplier other than Sanofi-Aventis Norge AS can deliver the product in the imminent contract period, and that the situation that has occurred is not the contracting authority’s fault, nor something that the contracting authority could foresee. LIS [the Pharmaceutical Division] therefore believes that there are grounds to make the procurement without an invitation to tender. See the public procurement regulations §21-5, c.f. § 21-2, c.f. § 13-4 letter b no. 3 and letter cf. also § 13-3 letter e.
LIS requests that any objections to this intention are submitted before the expiry of the waiting period, set to 23.06.2022. If no objections are received, contracts will be signed after the waiting period has expired.
LIS has explored the market situation and is of the opinion that it is impossible to hold a new contest or that a supplier other than Sanofi-Aventis Norge AS can deliver the product in the imminent contract period, and that the situation that has occurred is not the contracting authority’s fault, nor something that the contracting authority could foresee. LIS [the Pharmaceutical Division] therefore believes that there are grounds to make the procurement without an invitation to tender. See the public procurement regulations §21-5, c.f. § 21-2, c.f. § 13-4 letter b no. 3 and letter cf. also § 13-3 letter e.


Winner: Sanofi-Aventis Norge AS
Award value: 510000